Research institute
Investment in the German CRO, specialized in the preclinical assessment of new anticancer drugs, strengthens Citoxlab’s pharmacology portfolio, which will benefit from many synergies with preclinical safety and biomarkers services already provided by Citoxlab
CRISPR pioneer Jennifer Doudna has set up shop in San Francisco’s Gladstone Institutes. Doudna, a UC Berkley professor credited with the co-discovery of CRISPR-Cas9 genome editing technique, will focus on the development of new ways to implement the gene-editing technique for disease treatment.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Citing safety concerns, a watchdog organization is calling on the National institutes of Health to halt enrollment in a clinical trial evaluating a treatment for sepsis that the organization said is risky and flawed.
A new computer tool has been developed to predict how some cancers may respond to an investigational treatment before it has even been administered to a patient.
The NIH’s National Institutes on Aging (NIA) and the Alzheimer’s Association brought together various experts and stakeholders to create the National Strategy for Recruitment and Participation in Alzheimer’s Disease Clinical Research.
An article published earlier this summer in the Journal of Dental Research suggests that “bioengineered tooth buds” are a “superior alternative tooth replacement therapy.” In the article “Bioengineered Tooth Buds Exhibit Features of Natural Tooth Buds,” the authors report that artificial implants do not exhibit the same properties as natural teeth and are therefore subject to certain complications.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
The Cancer Prevention Institute of California (CPIC), located in Fremont, California, announced it was disbanding after 44 years. The reason for the closing, it indicates, is lack of federal funding.
Following a change to U.S. corporate tax laws, Pfizer announced at the beginning of this year that it intends to invest $5 billion in U.S. manufacturing over the next five years. On Tuesday, Pfizer showed its commitment to that promise with a $465 million investment in a new Michigan manufacturing site that is expected to create more than 450 jobs.
PRESS RELEASES